Last raised 01
700 USDm [CO006] Diligence report
Neko Health
Preventive health clinics with proprietary scanning hardware and a U.S. expansion story
Neko Health is a high-growth preventive-health clinic network with strong consumer demand and a premium brand, but the reported $7B valuation still outruns public evidence on revenue, reimbursement, and clinic economics.
Coverage and disclosure
Coverage reflects the fetched source bundle and the refreshed run date 2026-09-24. The public evidence set is strongest on funding, pricing, product workflow, and customer demand; it is weaker on audited revenue, clinic economics, reimbursement, and peer-reviewed clinical validation.
Cover facts
Company profile
Neko Health is a Stockholm-based preventive health company founded by Daniel Ek and Hjalmar Nilsonne. It sells a 60-minute scan that combines proprietary sensors, blood analysis, and clinician review, and it now operates across Sweden and the U.K. with a planned U.S. launch. The company has raised more than $1.0B and is being priced by the market as a premium consumer health network rather than a traditional medical-device vendor.
- Website
- www.nekohealth.com
- Founded
- 2018-01-01
- Founders
- Daniel Ek, Hjalmar Nilsonne
- Founding location
- Stockholm, Sweden
- Headquarters
- Stockholm, Sweden
- Product
- A one-hour preventive health scan that uses proprietary sensors, blood analysis, wearable data, and clinician review.
- Customers
- Affluent self-pay consumers seeking preventive reassurance and repeat annual checkups
- Business model
- Direct-to-consumer scan fees with repeat annual visits; no public insurer reimbursement path surfaced
- Stage
- Series C
- Funding status
- Series C completed in July 2026 for $700M; total capital raised now exceeds $1.0B
Executive summary
Top strengths
- Clear consumer value proposition with visible repeat behavior
- Vertically integrated hardware / software / clinical workflow
- Large raise gives runway for U.S. expansion
Top risks
- Clinical overdiagnosis and follow-up burden
- Capex-heavy clinic model with opaque payback
- Reported valuation far ahead of public revenue evidence
Open gaps
- Audited revenue, margin, and cash-balance disclosure is still missing
- Peer-reviewed clinical performance data for the core scan is still missing
- Clinic-level payback and U.S. reimbursement path remain unproven
Contents
01Company Overview
1.1 Identity and operating model
Neko Health is best understood as a premium preventive-health clinic network, not a software company. The company’s public story combines founder credibility, a simple consumer pitch, and a deliberately high-touch clinic experience. That combination matters because the investment case depends on whether a repeatable medical service can behave more like a consumer subscription than a one-off procedure. The company’s current footprint in Sweden and the U.K., along with the planned SoHo opening in New York, shows that the model has outgrown its original pilot stage. The unanswered question is not whether the brand can attract attention, but whether the operational system behind it can scale without destroying economics or clinical credibility.[CO001, CO002, CO009]
| metric | value/status | date | confidence | gap |
|---|---|---|---|---|
| founded | 2018 | 2018 | high | Exact day not disclosed |
| headquarters | Stockholm, Sweden | 2026-09-24 | high | None |
| founders | Daniel Ek; Hjalmar Nilsonne | 2018 | high | None |
| Series A | $65M | 2023-07-05 | high | None |
| Series B | $260M | 2025-01-23 | high | None |
| Series C | $700M | 2026-07-15 | high | Exact valuation not company-confirmed |
| latest valuation | ~$7B media-reported | 2026-07 | medium | Company did not confirm |
| scans completed | 100,000+ | 2026-08 | medium | No audited customer count |
| waitlist / registrations | 350,000+ | 2026-08 | medium | Registrations and waitlist are mixed |
| price | £299 / 2,750 SEK | 2026-09-24 | high | No U.S. price disclosed |
Current evidence only; the table mixes confirmed values and publicly reported estimates, and "gap" describes what is missing or ambiguous.
[CO001, CO003, CO004, CO006, CO007]| Person | Role | Background | Diligence implication |
|---|---|---|---|
| Daniel Ek | Co-founder | Spotify co-founder and public face of the company | Founder credibility and capital access remain central |
| Hjalmar Nilsonne | Co-founder and CEO | Operating lead for the clinic network and product rollout | Key execution owner for clinic scaling and quality |
Public coverage establishes the founder set, but it does not disclose a full management org chart or tenure history.
[CO001, CO009, CO010]1.2 Funding, valuation, and scale signals
The funding history is unusually aggressive for a company with limited public financial disclosure. The Series A and B are now historical, but the $700 million Series C is the key current event because it anchors the company’s public valuation narrative, its expansion plan, and its investor roster. Media and tracker sources converge on a valuation near $7 billion, but the company did not publicly confirm that figure in the source set we reviewed. That distinction is important: the round itself is real capital, yet the exact mark is still a reported number rather than a fully company-owned disclosure. The scale signals are also real. More than 100,000 scans and 350,000+ registrations imply meaningful demand, but they do not yet answer the harder question of conversion economics.[CO004, CO006, CO007, CO012]
The company moved from a 2018 founding story to a 2026 Series C and U.S. launch posture over a compact set of public milestones.
Founding [CO001]
First external round [CO006]
Scale inflection [CO004]
U.S. expansion signal [CO005]
First U.S. office opens [CO005]
1.3 Leadership, governance, and diligence gaps
The leadership story is straightforward enough to help the company sell the category. Daniel Ek brings founder fame and category credibility, while Hjalmar Nilsonne is the operating face of the business. The cap table now includes a mix of institutional venture backers and celebrity investors, which helps with distribution and publicity but does not substitute for operating evidence. The real diligence gap is still the same one that mattered before the latest round: no audited financials, no public margin detail, no disclosed insurance path, and no exact U.S. economics. Those are not minor omissions. They are the facts that determine whether the story is a premium clinic franchise or a durable health platform.[CO008, CO010, CO011]
| Stakeholder | Role | Economic importance | Diligence ask |
|---|---|---|---|
| Lightspeed Venture Partners | Series C lead investor | Anchor investor in the current funding round | Confirm ownership, board rights, and liquidation preference |
| O.G. Venture Partners | Series C co-lead investor | Major backer in the latest round | Confirm exact stake and governance rights |
| Atomico | Existing investor | Longstanding institutional backer | Map follow-on participation and dilution |
| General Catalyst | Existing investor | Scale-oriented venture backer | Confirm whether pro-rata rights were exercised |
| Lakestar | Existing investor | European venture backer | Verify relative ownership and any observer rights |
The map focuses on publicly named investors and omits unverified ownership percentages or preference-stack details.
[CO006, CO007, CO010]02Market Analysis
2.1 Market boundary and substitutes
The relevant market is not general healthcare. It is the overlap of preventive screening, longevity services, executive health checks, and private diagnostic alternatives that people buy to answer a simple question: am I healthy right now? The closest substitutes are annual physicals, lab panels, whole-body MRI, and status-quo symptom-driven care. Neko's pitch is that a single, non-invasive visit can reduce uncertainty faster and more pleasantly than those substitutes, but it still has to compete against more familiar and often cheaper habits of care. The category still leans on consumer psychology as much as medical proof, because people buy certainty and convenience together, not one or the other.[CM001, CM002, CM004, CM009]
| Segment / spend | Included | Excluded | Buyer / payer | Relevance |
|---|---|---|---|---|
| Preventive screening | Private scans, executive health, longevity checks | Emergency care, routine GP work | Consumer / employer | Direct market |
| Whole-body MRI | Premium imaging-based screening | General outpatient diagnostics | Consumer / self-pay | Primary substitute |
| Lab-first biomarker memberships | Blood panels and clinician interpretation | Imaging-heavy services | Consumer / employer | Adjacent substitute |
| Status quo annual physical | Routine checkups and symptom-driven care | Premium optional screening | Insurer / primary care | Baseline alternative |
This boundary intentionally excludes ordinary sick-care spending and focuses on self-directed preventive screening choices.
[CM001, CM002, CM009]2.2 Sizing lenses and adoption path
Multiple public sources point to a market that is large and growing, but the estimates vary depending on whether the lens is all preventive screening, just private direct-pay scanning, or a narrower convenience-health cohort. SNS Insider coverage cited a $29.7 billion market in 2025 rising to $47.2 billion by 2033, while competitor comparisons show why the customer can be affluent and self-pay even when insurance does not participate. Neko's realistic early buyers are high-income consumers, and later possibly employers or partner channels that want a premium health perk.[CM003, CM004, CM005, CM011]
| Lens | Publisher / source | Year | Geography | Value | CAGR | Methodology | Confidence | Limitation |
|---|---|---|---|---|---|---|---|---|
| Broad preventive screening market | SNS Insider via coverage | 2025 | Global | $29.7B | n/a | Market-report estimate | medium | Not specific to Neko's exact product |
| Forecast market | SNS Insider via coverage | 2033 | Global | $47.2B | 5-6%+ | Forward market projection | medium | Includes broader screening adjacencies |
| Direct-pay MRI and biomarker alternatives | Competitor coverage | 2026 | U.S./UK | n/a | n/a | Observed competitor pricing and scale | low | Fragmented and not fully measurable |
The table shows a lens set rather than one precise forecast because the public evidence mixes report data, competitor economics, and consumer willingness-to-pay.
[CM003, CM004, CM011]| Segment | Buyer | User | Payer | Workflow | Budget owner | Adoption trigger |
|---|---|---|---|---|---|---|
| Affluent consumer | Self | Self | Self-pay | Annual scan + clinician review | Household | Peace of mind / proactive screening |
| Employer wellness | Employer | Employee | Employer / subsidy | Benefit enrollment + repeat scans | HR / benefits | Retention and prestige |
| Partnership channel | Partner | Consumer | Partner / shared | Referral or bundled service | Partner P&L | Differentiated preventive offering |
| Clinical referral | Physician / specialist | Patient | Patient / insurer | Diagnostic follow-up | Medical budget | Unclear symptom or abnormality |
The map is directional: the company is clearly direct-to-consumer today, but the future buyer mix may widen if repeat demand is strong enough.
[CM005, CM011, CM012]Illustrative market layering from broad preventive screening to Neko's reachable self-pay subset.
Layer widths indicate hierarchy, not quantitative proportions.
Illustrative sizes are directional and intentionally conservative; only the broad market estimate is source-reported.
[CM003, CM004, CM011]2.3 Adoption constraints and diligence gaps
The main risk in this market is not lack of demand; it is whether the category creates more downstream cost and anxiety than value. Critical commentary on full-body scanning repeatedly highlights false positives, unnecessary follow-up, and the difficulty of proving long-term population-level benefit. That means the real adoption test is not just whether customers sign up once, but whether the service can keep producing enough meaningful findings to justify repeat annual spending, reimbursement support, or employer sponsorship over time. That is why the market can grow even while the evidence base stays contested: premium consumers may pay for reassurance before economists or regulators agree on the full value.[CM006, CM007, CM008, CM010, CM012]
03Competitors
3.1 Competitive landscape
The competitive set is broader than the company sometimes implies. Direct peers include MRI-based preventive screening providers such as Prenuvo and Ezra/Function Health, but the real comparison set also includes large imaging groups, lab-first membership products, and ordinary health-check pathways that already sit in the consumer's budget. Neko's launch into the United States matters because that is where the most scaled competitors already operate, and where the company will have to prove that its one-hour ritual is distinctive enough to overcome inertia and existing trust. The category also includes adjacent services like medical checkup bundles and longevity memberships, so the competitive boundary is fuzzy and can widen quickly as customers compare alternatives.[CP001, CP002, CP003, CP004]
| Competitor | Category | Scale / funding | Target segment | Differentiation | Limitation |
|---|---|---|---|---|---|
| Prenuvo | MRI screening | $192M funding / ~29 clinics | Affluent self-pay | MRI-based body scans | Higher price and heavier infrastructure |
| Function Health / Ezra | Lab + imaging membership | $2.5B valuation / Ezra acquired | Longevity consumers | Lab breadth and membership model | Less integrated clinic ritual |
| SimonMed | Imaging chain | Large multi-site operator | Broad consumer referrals | Installed imaging footprint | Not purpose-built for Neko-style membership |
| Quest / Labcorp | Lab networks | Mass-scale diagnostics infrastructure | Insured and self-pay patients | Payer and lab distribution | No proprietary scan ritual |
The profile table focuses on the companies that most clearly shape Neko's pricing and distribution choices in the U.S. and Europe.
[CP001, CP002, CP003, CP008]| Buying criterion | Neko Health | MRI peers | Lab-first peers | Status quo |
|---|---|---|---|---|
| Visit length | 60 minutes / same visit review | Longer, imaging-heavy | Often asynchronous | Standard primary care |
| Price | £299 / 2,750 SEK | $1,000-$2,700+ | Membership pricing | Insurance / copay |
| Hardware ownership | In-house sensors and workflow | Vendor / scanner dependent | Lab dependent | N/A |
| Consumer ritual | Highly designed clinic experience | Clinical imaging appointment | Data dashboard + labs | Annual physical |
Cells deliberately combine direct facts and judgment so the matrix reads as a buying decision aid rather than a marketing sheet.
[CP005, CP006, CP007, CP009]3.2 Positioning, pricing, and moat
Neko's price point is far below premium MRI alternatives, but the real moat may be the integrated experience rather than the scanner alone. The company owns the hardware, software, and clinic workflow, which makes the service harder to copy than a single imaging test. Still, lower switching costs and multi-homing mean consumers can try more than one preventive service, especially when the alternatives are also marketed as premium self-care. That makes distribution, partner access, and repeat-visit habit formation central to the moat question.[CP005, CP006, CP007, CP009, CP010]
| Company | Price / contract model | Included capabilities | Discounts / unknowns | Implication |
|---|---|---|---|---|
| Neko Health | £299 / year-like repeat scanning | Scan + clinician review + follow-up | U.S. pricing not disclosed | Middle-market premium |
| Prenuvo | $1,000-$2,700 per scan | MRI body scan | Package structure varies | Premium but more expensive |
| Function Health | Membership subscription | Labs + interpretation | Bundled membership economics | Competes on continuity |
| Status quo | Insurance / routine visits | Physical exam / routine labs | Co-pays and referrals | Default habit |
Pricing is not apples-to-apples, so the table emphasizes the customer's perceived trade-off instead of strict unit comparability.
[CP003, CP006, CP010]Evidence-backed placement by consumer ritual and product breadth.
| Item | X (1–4.5) | Y (1–4) | Context |
|---|---|---|---|
| 1. Neko Health | 4.5 | 4 | Integrated clinic ritual, mid-premium price |
| 2. Prenuvo | 3.5 | 3.4 | MRI-heavy, premium preventive imaging |
| 3. Function / Ezra | 2.8 | 3.8 | Membership-led labs plus imaging |
| 4. SimonMed | 2.2 | 2 | Scaled imaging operator, lower ritual depth |
| 5. Quest / Labcorp | 1.6 | 2.5 | Mass lab infrastructure and distribution |
| 6. Status quo primary care | 1 | 1 | Baseline annual physical and symptom-driven care |
3.3 Threats and diligence gaps
The most relevant threats are not just other startups; they are scaled imaging and laboratory franchises that can bundle preventive services into existing operations. Neko may have the better consumer ritual, but competitors with payer relationships, referral channels, or larger installed bases can still win if they move quickly enough. The open diligence question is whether a premium, cash-pay product can defend itself once the market matures and consumers learn that many of the same health questions can be answered by cheaper or reimbursed alternatives. In practice, the biggest question is whether Neko can keep attracting repeat buyers once competitor brands, referrals, and reimbursement-supported pathways become more familiar to consumers.[CP008, CP011, CP012]
04Financials
4.1 Funding chronology and valuation
Neko’s financing story is unusually fast-moving. The company has raised more than a billion dollars across three rounds, and the latest Series C is the event that changes the economic conversation because it is both large and valuation-setting. The public evidence supports the existence of the round and the broad valuation narrative, but not a full company-confirmed mark for the Series C itself. That matters because valuation without disclosed earnings is an expectations game. The market is pricing the expansion path, the brand, and the perceived category winner, not a mature cash flow stream. The evidence base is enough to trace round sizes and pricing anchors, but not enough to reconstruct audited unit economics. The evidence base is enough to trace round sizes and pricing anchors, but not enough to reconstruct audited unit economics.[CI001, CI002, CI003]
| stream | mechanism | unit | current value / status | quality | diligence ask |
|---|---|---|---|---|---|
| scan fees | Out-of-pocket consumer payment per visit | per scan | primary current stream | confirmed | What is realized revenue per scan? |
| repeat annual scans | Repeat visit after first scan | per year | important retention driver | confirmed | How many repeat members convert? |
| follow-up consultations | Clinician review and referrals | per visit | bundled into the scan | unclear | What portion is monetized separately? |
| U.S. expansion | New clinics in New York and beyond | site build | funded by Series C | planned | What is site payback? |
| European expansion | Additional clinics and capacity | site build | ongoing | planned | What is the margin by city? |
| enterprise / employer channel | Potential B2B distribution | contract | not disclosed | hypothetical | Any signed contracts? |
| insurance reimbursement | Payer coverage | coverage | not public | absent | Is there any payer path? |
| data / analytics | Longitudinal health data value | unknown | not disclosed | hypothetical | Any separate monetization? |
| device / service package | Bundled clinic experience | package | current product | confirmed | What is gross margin by package? |
| clinical follow-up | Referrals and escalations | per case | not public | opaque | Who pays and who owns it? |
Mixed current, planned, and hypothetical streams; the notes column describes the evidence gap or monetization question for each stream.
[CI001, CI003, CI004, CI005, CI006]| Market | Price | Access channel | Diligence implication |
|---|---|---|---|
| UK | £299 | Direct consumer booking | Confirms a premium self-pay entry point |
| Sweden | 2,750 SEK | Direct consumer booking | Gives the clearest public price anchor |
| U.S. | Not yet disclosed | Pending New York rollout | U.S. pricing remains an open diligence item |
The table isolates publicly visible price points and leaves U.S. monetization unresolved.
[CI001, CI002, CI003, CI004, CI005]4.2 Monetization and cost structure
The present model is straightforward: consumers pay per scan, repeat annually if they like the result, and receive a clinician review as part of the bundle. The problem is that the unit economics are not fully visible. Each clinic requires real estate, devices, and staff, and the company has not published a clinic margin or payback calculation. That makes it hard to tell whether the business is a premium service business with healthy returns or a growth story that simply consumes capital to buy time. The evidence supports a premium product with strong demand signals; it does not yet prove a self-funding clinic network.[CI004, CI005, CI006]
| Round | Amount | Date | Lead / context | Implication |
|---|---|---|---|---|
| Series A | $65M | 2023 | Early venture round | Establishes outside capital formation |
| Series B | $260M | 2025 | Institutional growth round | Shows continued scaling appetite |
| Series C | $700M | 2026 | Lightspeed and O.G. Venture Partners | Anchors the current balance-sheet story |
Funding amounts are drawn from public reporting and should be read as disclosed round sizes, not audited cash balances.
[CI001, CI002, CI003, CI004, CI005]4.3 Capital adequacy and forward needs
The Series C gives Neko a large runway to build out its U.S. plan, but the source set does not tell us how much cash the company had before the round or how quickly it burns through that capital. That means the real question is not whether the company can continue operating, but whether it can open enough clinics and preserve service quality before the next financing decision. In other words, the raise buys option value. It does not yet prove that the unit economics are good enough to make the model independent of future capital. That still leaves clinic economics and burn discipline as the real underwriting bottlenecks. Those assumptions are directional only, not yet audited.[CI007, CI008, CI009]
The company moved from founder-backed scale-up to a heavily capitalized expansion phase between the first external round and the New York launch.
| Node / Connection | Node / from | To | Context |
|---|---|---|---|
| Node 1 | Funding rounds [funding] | ||
| Node 2 | List pricing [pricing] | ||
| Node 3 | Scale signals [scale] | ||
| Node 4 | Unknown unit economics [economics] | ||
| Node 5 | Unknown runway [runway] | ||
| Node 6 | Forward capital need [capital] | ||
| Connection 1 | Funding rounds [funding] | List pricing [pricing] | |
| Connection 2 | List pricing [pricing] | Scale signals [scale] | |
| Connection 3 | Scale signals [scale] | Unknown unit economics [economics] | |
| Connection 4 | Unknown unit economics [economics] | Unknown runway [runway] | |
| Connection 5 | Unknown runway [runway] | Forward capital need [capital] |
05Product & Technology
5.1 What the product is
Neko’s product is a one-hour preventive-health visit, not a software dashboard. The customer pays for a scan, bloodwork, and a clinician conversation that turns measurements into a health summary and follow-up plan. The experience is deliberately designed to feel reassuring rather than medical-argon heavy. That is important because the company is selling repeat behavior. If the first visit feels confusing or scary, the annual model weakens. If it feels easy, legible, and useful, the product can become a habit. The public evidence strongly supports the consumer-facing workflow; it does not yet prove that the clinical signal is enough to justify broad medical adoption. The public evidence also suggests an operationally complex stack rather than a simple consumer gadget, which matters because any technical moat depends on reproducibility, quality control, and follow-through. The public evidence also suggests an operationally complex stack rather than a simple consumer gadget, which matters because any technical moat depends on reproducibility, quality control, and follow-through.[CE001, CE002, CE009]
| module / asset | user | status / maturity | differentiation | diligence gap |
|---|---|---|---|---|
| scan experience | consumer / clinician | live | single branded one-hour visit | peer-reviewed performance |
| sensor stack | clinical system | in-house | high-density data capture | exact modality mix |
| blood analysis | patient | live | same-visit review | lab workflow details |
| wearables integration | member | recently added | longitudinal context | data permission model |
| body composition | member | recently added | broader health picture | measurement validation |
| Derma-2 / Echo-2 / Spectrum-2 | clinic operations | rolling out | automation and fidelity | deployment schedule |
| clinician review | doctor | core | human trust layer | capacity per clinician |
| data platform | operations / engineering | active | secure workflows | stack disclosure |
| Workday / HRIS integrations | people ops | active build | operational maturity | integration reliability |
| privacy / quality controls | all users | necessary | trust foundation | public compliance evidence |
This table mixes customer-facing and operational modules because Neko’s product moat depends on both the scan itself and the systems that keep it repeatable.
[CE001, CE002, CE003, CE004, CE005]| Step | Input | Output | Operational risk |
|---|---|---|---|
| Booking / intake | Consumer appointment and pre-visit screening | Scheduled scan slot | No-show or mismatch risk |
| Scanning | Body scan and physiological capture | Raw biometric dataset | Device uptime and throughput risk |
| Review | Clinician review plus analysis workflow | Interpreted result | Consistency and clinical-quality risk |
| Follow-up | Consumer report and next-step guidance | Actionable output | Retention and trust risk |
The workflow is intentionally simplified; the public source set does not provide a full SOP or QA manual.
[CE001, CE002, CE003, CE004, CE005]5.2 How it works and what changed
The source set describes a vertically integrated stack: proprietary sensors, blood analysis, clinician review, and an internal software layer that now includes wearables and body composition. The recent device refresh suggests the product is still improving, which is good news for customers but also a reminder that this is an evolving system rather than a frozen platform. The key technical claim is not just that the scan exists, but that repeat measurements can create a better longitudinal model over time. That claim is plausible and important. It is also the one most dependent on data quality and clinical rigor. That long-lived stack matters because longitudinal measurement is only useful if the data plumbing stays stable.[CE003, CE004, CE006, CE007]
| Layer | Function | Visible evidence | Diligence question |
|---|---|---|---|
| Hardware | Sensors and scan hardware | Public product pages and launch coverage | What portion is proprietary versus sourced? |
| Software | Result analysis and workflow control | Consumer experience and software messaging | How much is automated versus manual? |
| Clinical layer | Clinician interpretation and safety review | Medical positioning in sources | How standardized is the clinical protocol? |
| Operations | Clinic throughput and QA | Expansion coverage and hiring signals | What is the per-site throughput ceiling? |
This table frames the stack as an operating system for clinics rather than a pure consumer gadget.
[CE001, CE002, CE003, CE004, CE005]5.3 Trust, safety, and validation gaps
The current evidence set is strongest on workflow and weakest on validation. Hiring pages show a real operational stack, but they do not substitute for a published performance paper or a regulator-approved claims package. That gap matters because a preventive scan can create follow-up burden as easily as it creates value. The right diligence question is therefore not whether the product is polished. It is whether the product can be trusted to find meaningful issues without producing too many noisy referrals or compliance surprises. On the material we reviewed, the answer is still partially open. That gap matters because preventive screening only compounds value if the underlying measurement stack remains trustworthy over repeated annual visits.[CE005, CE008, CE010, CE011, CE012]
The product narrative progresses from scan capture to clinical review, but validation evidence is still lighter than the commercial story.
- Consumer workflow
- 60-minute preventive scan, bloodwork, and same-visit clinician review for the customer experience
- Sensor and lab stack
- Proprietary sensors, blood analysis, and measurement capture that create the raw diagnostic data
- Wearables and body composition
- Longitudinal context and broader health signals added to the scan experience
- Clinical review and follow-up
- Human clinician interpretation, routing, and escalation of meaningful findings
- Operations and compliance
- Data handling, HRIS/workflow integrations, privacy controls, and quality checks
- Governance and data controls
- Privacy, compliance, and quality controls that keep the clinic workflow repeatable and trustable
06Customers
6.1 Who pays and why
Neko’s current customer is the affluent self-paying consumer. That customer is buying reassurance, a baseline health picture, and a polished preventive experience. The important thing is that the buyer, user, and payer are usually the same person right now. That keeps the model simple, but it also caps the audience to people who can afford repeated annual screening. The evidence suggests the company is winning with this segment because it is clear, high-intent, and emotionally resonant. The model becomes much harder if the company tries to broaden to lower-income households or wait for insurers to carry the bill. The customer story therefore hinges on whether the waitlist converts into repeatable visits rather than one-time publicity. The customer story therefore hinges on whether the waitlist converts into repeatable visits rather than one-time publicity.[CU001, CU006, CU009]
| segment | buyer / user / payer | use case | scale | revenue / strategic value | gap |
|---|---|---|---|---|---|
| affluent self-pay consumer | buyer=user=payer | annual preventive scan | core today | primary revenue | conversion funnel |
| repeat customer | buyer=user=payer | annual re-scan | growing | retention value | cohort length |
| New York launch queue | buyer=user=payer | first-time scan | early | launch signal | actual conversion |
| UK / Sweden urban professional | buyer=user=payer | reassurance and baseline health | core | repeatability | city-level concentration |
| biohacker / longevity enthusiast | buyer=user=payer | status and measurement | early adopter | brand halo | broadness of appeal |
| employer channel | payer maybe employer | workforce wellness | possible | distribution leverage | signed contracts |
| insurer / reimbursement channel | payer insurer | preventive screening | not visible | scale unlock | coverage evidence |
| family / couple purchase | buyer pair | shared reassurance | possible | basket size | repeat path |
| clinical follow-up recipient | patient / provider | actionable next steps | important | trust and outcomes | follow-up ownership |
| brand-driven early adopter | buyer=user=payer | experience and novelty | visible | PR and referral | sustained usage |
The table separates buyer, user, and payer because those roles are currently the same in the core model and only later may diverge through employer or insurer channels.
[CU001, CU002, CU003, CU004, CU005]| Segment | Why they buy | Evidence | Risk |
|---|---|---|---|
| Affluent self-pay consumers | They value prevention and premium access | Price points and waitlist coverage | Demand may remain niche |
| Health-conscious repeat visitors | They may return for reassurance and monitoring | Scan-count claims | Repeat frequency is unproven |
| U.S. early adopters | They respond to brand and novelty | SoHo launch coverage | Conversion from waitlist to visits is unknown |
| International travelers / expats | They seek premium care while traveling | Multi-city footprint | Cross-border demand may be sporadic |
The table describes likely demand buckets, not a formal CRM segmentation model.
[CU001, CU002, CU003, CU004, CU005]6.2 Adoption proof and durability
The adoption data are strong enough to say the product has real pull. More than 100,000 scans and a 75% rebooking rate are not trivial numbers, especially for a physical clinic service. Those metrics tell us that customers are not just curious; many come back. Still, the proof is mostly about enthusiasm and repeated habit, not yet about broader market conversion or enterprise distribution. The exact funnel is opaque, the payer mix is narrow, and the public evidence does not show a large employer or insurer channel. So the customer thesis is real, but it is still concentrated in a premium niche. Strong repeat behavior is encouraging, but the public evidence still stops short of a full renewal or cohort analysis.[CU002, CU003, CU004, CU008, CU011]
| Proof point | Current signal | Open question | Why it matters |
|---|---|---|---|
| Completed scans | 100,000+ public figure | How many are repeat or referral-driven? | Tests product stickiness |
| Waitlist / registrations | 25,000+ New Yorkers and broader registrations | How much converts to paying visits? | Tests U.S. launch traction |
| Geographic footprint | Sweden, UK, and New York entry | How quickly can coverage scale? | Tests operating replication |
| Price point | £299 / 2,750 SEK | Will U.S. pricing hold demand? | Tests monetization elasticity |
This table keeps the customer proof discussion anchored in observable public signals.
[CU001, CU002, CU003, CU004, CU005]6.3 Expansion and concentration risk
The geographic story is encouraging and dangerous at the same time. Neko has moved from Stockholm into the U.K. and is now preparing a New York launch, which shows the experience can travel. But the current customer base is still concentrated in a small number of urban pockets, and the source set does not show evidence of payer diversification. That means the customer story is not yet a broad healthcare channel story. It is a premium urban consumer story with strong repeat behavior. The next diligence question is whether that story can be duplicated city by city without losing conversion or raising support costs too sharply. The open question is whether that premium story can widen without compressing conversion or lifting support costs too sharply.[CU005, CU007, CU010, CU012]
The customer path starts with brand awareness and ends with repeat visits or referrals, but conversion quality remains the key unknown.
[CU002, CU003, CU004, CU008, CU012]07Risks
7.1 Clinical and reimbursement risk
The biggest risk is not that the product exists; it is that the product finds too much that does not matter. False positives and follow-up cascades are the canonical critique of full-body scanning, and the source set repeats that criticism from multiple angles. The reimbursement issue compounds the problem. If customers pay out of pocket, the market stays premium and limited. If a payer never enters the model, growth stays tied to discretionary spend. That combination can still support a strong business, but it also means the company’s downside is not just product failure. It is category refusal at scale. Taken together, these risks matter less as abstract downside labels than as direct drivers of slower bookings, thinner margins, and harder valuation support. Taken together, these risks matter less as abstract downside labels than as direct drivers of slower bookings, thinner margins, and harder valuation support. The central diligence test is whether those warnings are manageable or structural.[CR001, CR002, CR012]
| risk | why it matters | current evidence | severity | diligence ask |
|---|---|---|---|---|
| false positives | Can create expensive follow-up cascades | criticized by adverse sources | high | What are the false-positive rates? |
| reimbursement | Limits market size and affordability | no visible payer path | high | Any coverage or employer contracts? |
| clinic capex | Sites are expensive and slow to build | clinic model visible | high | What is site payback? |
| staffing | Requires clinicians and ops support | hiring evidence visible | medium | What is clinician productivity? |
| U.S. regulation | New market adds liability and process risk | launch planned | medium | Any FDA / state path? |
| privacy / data | Health data is sensitive | stack is multi-layered | medium | What controls are public? |
| valuation compression | Narrative can outrun economics | public revenue thin | high | What is the real revenue base? |
| city concentration | A few sites matter a lot | visible in rollout | medium | What is the diversification plan? |
| follow-up burden | Could externalize costs | highly plausible | high | Who owns escalation? |
| outcomes proof | Clinical claims need evidence | still incomplete | high | Where are the endpoints? |
Risk register rows combine product, operational, and market risks because Neko’s downside is a mix of medicine and execution.
[CR001, CR002, CR003, CR004, CR005]| Risk | Why it matters | Public mitigation | Residual gap |
|---|---|---|---|
| Regulatory / reimbursement | Determines whether the business stays self-pay only | Premium consumer positioning | No disclosed reimbursement path |
| Throughput | Clinic economics depend on per-site volume | Operational expansion and hiring | No public capacity model |
| Customer concentration | A narrow fan base can limit durability | Broad waitlist and brand awareness | No disclosed cohort mix |
| Execution | Rolling out new clinics requires repeatability | New York launch and funding | No public site-level margin data |
The table is deliberately risk-first and is not meant to imply the company has already failed these tests.
[CR001, CR002, CR003, CR004, CR005]7.2 Capital, staffing, and rollout risk
Neko’s clinic model is expensive to grow. Every new site needs real estate, hardware, clinicians, and a well-managed follow-up path. The hiring footprint shows a real operating company, but it also shows how many systems have to work at once. That makes execution risk very real. The company can certainly spend the Series C on growth, but spending alone does not prove attractive economics. If productivity or conversion disappoints in any key city, the valuation story compresses quickly. In other words, growth is not the same thing as scalability.[CR003, CR007, CR009, CR010]
| Source | Stance | Key warning | Topic |
|---|---|---|---|
| ValueAddVC | adverse | Valuation looks media-led rather than company-confirmed | valuation |
| Angel Investors Network | adverse | The $7B number is treated as estimate, not disclosure | valuation |
| A skeptical market-data source | adverse | Revenue, margin, and payback remain thinly evidenced | financial opacity |
The adverse set is used to keep the risk chapter anchored in warning signals, not only company optimism.
[CR001, CR002, CR003, CR004, CR005]7.3 Data, regulation, and proof gaps
The evidence set is reassuring in one narrow sense: there is no obvious major litigation or enforcement event surfaced here. But that does not solve the proof problem. The company still lacks a public outcomes dossier, a regulator-facing evidence package, or a clear payer path. The risk is therefore less about a single catastrophic event and more about accumulated uncertainty. Until the company shows outcomes, privacy controls, and controlled follow-up economics, investors should treat the story as attractive but incomplete. The practical question is whether repeated screening can stay attractive if follow-up burden, regulation, or pricing pressure rise together. The follow-up question is whether the model scales faster than its downside externalities.[CR004, CR005, CR006, CR008, CR011]
Clinical and financial risks dominate residual exposure; operational and partner risks are more manageable but still material.
Qualitative assessment derived from public evidence; not actuarial scoring.
[CR001, CR002, CR003, CR004, CR005, CR006]08Valuation
8.1 What the market is paying for
The market is paying for a future category winner, not a mature clinic chain. The best-supported mark is a reported figure near $7 billion, but the company has not publicly confirmed that exact price in the source set we reviewed. The point is not that the number is fake; it is that it is directional. Investors are pricing brand, expansion, and repeat behavior. That can be rational in a category with large upside. It also means the valuation is fragile if the U.S. rollout stumbles or if repeat annual usage fades after the novelty wears off. The valuation view is therefore a judgment about how much of the current premium is justified by evidence versus story. The valuation view is therefore a judgment about how much of the current premium is justified by evidence versus story.[CV001, CV003, CV009]
| lens | value | implied view | confidence | note |
|---|---|---|---|---|
| reported Series C valuation | ~$7B | headline market price | medium | Media-reported, not company-confirmed |
| Series B valuation | $1.8B | prior anchor | high | Visible in multiple sources |
| Series C capital raised | $700M | growth fuel | high | Company-confirmed amount |
| total capital raised | $1.025B | scale proxy | high | Round-sum total |
| 2025 revenue estimate | $21.9M | small base | medium | Estimated by GetLatka |
| valuation / revenue | very high | premium growth pricing | medium | Derived from estimate |
| U.S. rollout option value | high | future upside | medium | Depends on execution |
| peer comparison | premium | expensive versus mature imaging | medium | Not directly comparable |
| downside band | well below headline | compression risk | medium | If growth misses |
| stance | expensive / track | do not underwrite as mature cash flow | medium | Balance of evidence |
The table intentionally mixes hard numbers and analytical lenses because the valuation question is partly factual and partly judgmental.
[CV001, CV002, CV003, CV004, CV005]| Signal | Evidence | Upward interpretation | Downward interpretation |
|---|---|---|---|
| Series C | $700M of new capital | Strong external confidence | Round size does not prove operating quality |
| Media valuation | ~$7B reported | Shows market appetite | Not company-confirmed |
| Scale signal | 100,000+ scans | Suggests product-market pull | No audited unit economics |
| Market expansion | U.S. launch | Potential new demand pool | Execution risk remains high |
This bridge distinguishes hard funding evidence from softer valuation narratives.
[CV001, CV002, CV003, CV004, CV005]8.2 What the math implies
Even using a simple public revenue estimate, the implied multiple is rich. That does not automatically make the company a bad investment, but it does mean the case depends on a lot of future execution. The upside scenario is straightforward: replicate clinics, preserve retention, and scale the brand into a much larger preventive-health network. The downside scenario is also straightforward: the company stays a premium niche with solid demand but insufficient economic density to justify a top-tier growth mark. The current evidence fits neither extreme perfectly, which is why the right answer is to treat the valuation as expensive, not impossible.[CV002, CV004, CV005, CV011]
| Framing | What it compares | Useful for | Limit |
|---|---|---|---|
| Premium preventive care | Consumer willingness to pay for health reassurance | Testing willingness-to-pay | Does not capture clinic scale economics |
| Diagnostics network | Operational throughput and clinical workflow | Thinking about site efficiency | Does not resolve reimbursement |
| Consumer subscription | Brand and repeat-use behavior | Thinking about retention | Does not match the full service scope |
The comparable set is conceptual; the source set does not support a clean public comps table.
[CV001, CV002, CV003, CV004, CV005]8.3 Recommended stance
The correct stance on the public evidence is not blind enthusiasm and not outright dismissal. It is to recognize that Neko is still in the option-value phase of the story. The company has real demand, real capital, and a real expansion plan. It does not yet have the audited financial detail, precision valuation data, or clinic economics that would let an investor call the mark reasonable on fundamentals alone. So the valuation should be treated as expensive and execution-sensitive, with upside still available if the U.S. rollout proves the model can scale without breaking the customer experience. The right stance is to underwrite upside only if the public evidence catches up to the price, not before. The point is not perfection; it is whether the public evidence can justify the current price with enough margin of safety.[CV006, CV007, CV008, CV010, CV012]
The valuation call flows from demand and capital into the missing economics, risks, and eventual stance.
| Node / Connection | Node / from | To | Context |
|---|---|---|---|
| Node 1 | Demand and brand [demand] | ||
| Node 2 | Capital raised [capital] | ||
| Node 3 | Missing economics [economics] | ||
| Node 4 | Clinical / rollout risk [risks] | ||
| Node 5 | Reported valuation [valuation] | ||
| Node 6 | Track / expensive [stance] | ||
| Connection 1 | Demand and brand [demand] | Capital raised [capital] | |
| Connection 2 | Capital raised [capital] | Missing economics [economics] | |
| Connection 3 | Missing economics [economics] | Clinical / rollout risk [risks] | |
| Connection 4 | Clinical / rollout risk [risks] | Reported valuation [valuation] | |
| Connection 5 | Reported valuation [valuation] | Track / expensive [stance] |
Disclaimer
This report is based on the fetched source bundle for run 20260924030112-neko-health and is intended for diligence, not medical advice or investment advice.
Evidence index
| ID | Statement | Confidence | Sources |
|---|---|---|---|
| CO001 | Neko Health was founded in 2018 by Daniel Ek and Hjalmar Nilsonne and is headquartered in Stockholm, Sweden. | High | SO001, SO007 |
| CO002 | Neko Health sells a 60-minute preventive health scan that combines proprietary sensors, blood analysis, and clinician review. | High | SO002, SO005 |
| CO003 | The current list price is £299 in the UK and 2,750 SEK in Sweden. | High | SO002, SO005 |
| CO004 | The company says it has already surpassed 100,000 completed scans and roughly 350,000 registrations or waitlist entries. | High | SO002, SO005, SO003 |
| CO005 | Neko Health will open its first U.S. office in SoHo, Manhattan, on September 24, 2026 at 300 Lafayette Street. | Medium | SO002 |
| CO006 | The company closed a $700 million Series C in July 2026 led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. | Medium | SO003, SO005, SO007 |
| CO007 | Secondary reporting places the post-money valuation near $7 billion, while the company did not publicly disclose that number in the source set we reviewed. | Medium | SO004, SO006, SO003 |
| CO008 | The public source set leaves revenue, gross margin, reimbursement, and clinic-level payback largely undisclosed. | Medium | SO004, SO008, SO006 |
| CO009 | The company has expanded from Sweden into multiple U.K. cities and is now preparing a U.S. entry. | High | SO002, SO005, SO003 |
| CO010 | The investor base now includes Lightspeed, O.G. Venture Partners, Atomico, General Catalyst, Lakestar, and high-profile individual backers. | Medium | SO005, SO003, SO007 |
| CO011 | Tracker sources disagree on current headcount, so the exact employee count should be treated as unverified rather than precise. | Medium | SO007, SO008 |
| CO012 | The company’s operating footprint now extends beyond a pilot clinic and looks like a multi-site consumer health network. | Medium | SO002, SO005, SO003 |
| CM001 | Neko Health sits in the preventive screening and longevity-services market rather than in acute care or primary care. | Medium | SM001, SM003, SM004 |
| CM002 | The closest substitutes are annual physicals, lab panels, whole-body MRI, and conventional symptom-driven care. | High | SM001, SM007, SM008 |
| CM003 | Public market coverage cited a $29.7 billion market in 2025 that could reach $47.2 billion by 2033. | High | SM001, SM005 |
| CM004 | Whole-body MRI competitors are materially more expensive than Neko's £299 / 2,750 SEK scan. | High | SM001, SM007 |
| CM005 | The early adoption path starts with affluent self-pay consumers and can broaden to employers or partners if repeat demand stays strong. | Medium | SM001, SM005, SM006 |
| CM006 | The U.S. launch is a meaningful market test because the market is larger, but also more fragmented and liability-sensitive. | High | SM004, SM006 |
| CM007 | False positives can create expensive follow-up cascades that outweigh some of the scan's upfront simplicity. | Medium | SM003, SM004 |
| CM008 | The public evidence does not yet show population-level outcome proof, reimbursement support, or a stable conversion funnel from interest to repeat annual purchases. | Medium | SM001, SM004, SM006 |
| CM009 | Neko competes not only with MRI-based screening but also with ordinary annual physicals and insurer-covered care that people already trust. | Medium | SM001, SM003, SM008 |
| CM010 | Consumer willingness to pay remains the key market signal, because the current model is still mostly cash-pay. | Medium | SM001, SM006 |
| CM011 | Market growth is being pulled by convenience, early detection, and premium health-status anxiety rather than by insurance reimbursement. | Medium | SM001, SM005, SM006 |
| CM012 | The biggest diligence gap is that broad market enthusiasm does not yet equal proof that annual scanning improves long-term outcomes. | Medium | SM003, SM004, SM005 |
| CP001 | Neko Health competes directly with MRI-based preventive screening brands such as Prenuvo and Function Health / Ezra. | Medium | SP001, SP004, SP005 |
| CP002 | Tracxn lists 138 active competitors, showing that the category is crowded rather than empty. | Medium | SP005 |
| CP003 | Prenuvo has raised about $192 million and operates roughly 29 clinics, making it one of the clearest scaled MRI peers. | Medium | SP001, SP004 |
| CP004 | Function Health reached a $2.5 billion valuation after raising $298 million and then acquired Ezra. | Medium | SP001, SP004 |
| CP005 | Neko Health undercuts MRI competitors on price with a £299 scan while keeping a one-hour clinic ritual. | High | SP004, SP007 |
| CP006 | Neko's moat comes from its vertical integration across hardware, software, and clinic workflow rather than from the scanner alone. | Medium | SP006, SP008 |
| CP007 | Switching costs appear moderate because consumers can multi-home across a scan provider, a lab membership, and a primary-care path. | Medium | SP001, SP005, SP007 |
| CP008 | Large incumbents such as Quest and Labcorp can still attack the market if they bundle preventive services into existing distribution. | Medium | SP001, SP004, SP008 |
| CP009 | SimonMed and other imaging operators can imitate some of the service model but not necessarily the same brand ritual or in-house stack. | Medium | SP001, SP005 |
| CP010 | Neko's U.S. launch cities are especially competitive because they already have affluent consumers and scaled diagnostic options. | Medium | SP007, SP008 |
| CP011 | The most likely future entrants are AI-enabled imaging, lab, or longevity startups that can bundle preventive services with adjacent offerings. | Medium | SP002, SP005, SP006, SP009 |
| CP012 | The category likely consolidates around a few brands only if repeat visits and reimbursement or employer sponsorship improve over time. | Medium | SP002, SP006, SP008, SP009 |
| CI001 | Neko Health has raised roughly $1.025 billion across the Series A, B, and C rounds. | Medium | SI001, SI002, SI003, SI004 |
| CI002 | The Series B priced the company at $1.8 billion, while the Series C valuation is widely reported near $7 billion rather than directly company-confirmed. | Medium | SI009, SI010, SI011, SI012 |
| CI003 | GetLatka estimates 2025 revenue at about $21.9 million, but that remains an estimate rather than an audited figure. | Medium | SI008, SI009 |
| CI004 | Neko monetizes directly through per-scan fees today, with no public evidence of insurance reimbursement. | Medium | SI003, SI005, SI006 |
| CI005 | At £299 and 2,750 SEK per scan, the company needs high repeat usage or strong clinic throughput to produce attractive revenue. | Medium | SI006, SI007, SI003 |
| CI006 | The operating model is capital intensive because each clinic requires space, devices, clinicians, and follow-up capacity. | Medium | SI005, SI006, SI007 |
| CI007 | The Series C proceeds are aimed at U.S. launch and continued technology investment rather than a financial restructuring. | Medium | SI011, SI012, SI009, SI004 |
| CI008 | The source set does not reveal cash on hand, burn rate, or runway, so capital adequacy cannot be underwritten directly. | Medium | SI011, SI012, SI008 |
| CI009 | Clinic-level profitability is not public, and the source set does not support a clean payback-period estimate. | Medium | SI004, SI008 |
| CI010 | Reported valuation is growing much faster than public revenue evidence, which suggests the market is valuing future expansion more than current earnings. | Medium | SI002, SI007, SI008 |
| CI011 | The company appears to need enough capital to bridge the U.S. clinic build-out before economics can be observed at scale. | Medium | SI004, SI006 |
| CI012 | No public debt or project-finance facility surfaced in the evidence set, so equity remains the visible funding mode. | Medium | SI001, SI003 |
| CE001 | Neko Health delivers a 60-minute, non-invasive scan that combines proprietary sensors, blood analysis, and clinician review. | High | SE010, SE011, SE001 |
| CE002 | The product now includes body composition analysis and wearable-data review, extending the scan beyond one-off measurement. | High | SE010, SE011, SE003 |
| CE003 | Neko engineers hardware, software, and clinical protocols in-house rather than outsourcing the whole stack. | High | SE010, SE011, SE002 |
| CE004 | The next-generation devices named Derma-2, Echo-2, and Spectrum-2 are being rolled out to improve automation and signal quality. | Medium | SE001, SE003 |
| CE005 | The technical due-diligence source says the system uses more than 70 sensors and can collect roughly 50 million data points with sub-millimeter skin detection. | Medium | SE001, SE010 |
| CE006 | The hiring footprint shows a secure health-data platform and Workday integration environment, which implies a fairly complex internal operating stack. | Medium | SE002, SE004, SE005 |
| CE007 | The product’s defensibility depends on longitudinal repeat measurement, not just one-time detection. | Medium | SE005, SE007 |
| CE008 | The evidence set does not surface a peer-reviewed sensitivity/specificity paper or a clean regulatory dossier for the core scan. | Medium | SE001, SE004, SE005 |
| CE009 | The customer experience is designed to reduce anxiety by giving same-visit results and a clinician conversation. | Medium | SE001, SE003 |
| CE010 | Operational roles point to an Azure-backed backend and cross-functional systems integration surface rather than a single-purpose app. | Medium | SE005, SE006, SE008 |
| CE011 | Safety and privacy obligations are material because the product mixes imaging, bloodwork, and longitudinal health data. | Medium | SE002, SE003, SE004 |
| CE012 | The available evidence supports a polished consumer health workflow, but not a fully transparent technical validation story. | Medium | SE001, SE004, SE005 |
| CU001 | The primary buyer is the affluent self-paying consumer who wants preventive reassurance rather than symptom-driven care. | Medium | SU001, SU003, SU005 |
| CU002 | The company says more than 100,000 scans have been completed and 350,000+ registrations or waitlist entries exist. | High | SU001, SU002, SU009 |
| CU003 | Repeated booking is strong: the source set says about 75% of members prepay for the next annual scan. | Medium | SU002, SU003, SU009 |
| CU004 | The early customer base appears concentrated in Stockholm, London, and now New York’s launch queue. | Medium | SU001, SU003, SU004 |
| CU005 | Named customer-style proof is mostly indirect: case-study and commentary sources praise the experience, but not many named enterprise deployments appear. | Medium | SU006, SU007, SU013 |
| CU006 | The earliest adopters appear to be health-conscious, affluent, and novelty-tolerant consumers rather than mass-market households. | Medium | SU003, SU004, SU005 |
| CU007 | The source set does not show insurer coverage or a large employer contract that would broaden the customer mix. | Medium | SU007, SU008 |
| CU008 | New York’s 25,000-person waitlist indicates demand, but it is still a city-level early-adopter signal rather than proof of broad conversion. | High | SU001, SU009 |
| CU009 | The customer journey is designed as a repeated annual habit, not a one-time medical event. | Medium | SU003, SU005 |
| CU010 | The company’s customer evidence is strong on enthusiasm and weaker on exact cohort conversion math. | Medium | SU004, SU005, SU008 |
| CU011 | Retention appears durable enough to support a premium annual model, but not yet broad enough to prove mass adoption. | Medium | SU002, SU003, SU005 |
| CU012 | The customer story is still centered on affluent urban pockets, with broader geographic expansion still ahead. | Medium | SU001, SU004, SU005 |
| CR001 | False positives and follow-up cascades are the core clinical criticism of full-body scanning. | Medium | SR012, SR009, SR006 |
| CR002 | The scan is cash-pay and not shown to be reimbursed, so affordability remains a real adoption risk. | High | SR006, SR008, SR010 |
| CR003 | Each clinic requires physical space, devices, clinicians, and support staff, making the model capital intensive. | Medium | SR012, SR005 |
| CR004 | The U.S. launch adds regulatory and liability complexity beyond the company’s current European footprint. | Medium | SR006, SR005, SR009 |
| CR005 | The product touches imaging, bloodwork, and longitudinal health data, so privacy and data-handling risk should be monitored closely. | Medium | SR012, SR006 |
| CR006 | Reported valuation can compress quickly if growth or retention slows because the public revenue base is thin. | Medium | SR007, SR005 |
| CR007 | The current business remains concentrated in a few premium cities, which creates execution risk if any one market underperforms. | Medium | SR005, SR012 |
| CR008 | The source set does not show a peer-reviewed outcomes dossier or a decisive payer pathway. | Medium | SR012, SR010 |
| CR009 | Staffing complexity is visible in the hiring footprint, which implies operational scaling risk. | Medium | SR007, SR008 |
| CR010 | The backer mix can amplify the story, but it does not remove medical or economic risk. | Medium | SR009, SR010 |
| CR011 | The evidence set does not show a major litigation, recall, or regulatory enforcement event, which is reassuring but not de-risking. | Medium | SR001, SR002, SR006 |
| CR012 | The company has to prove that it can scale without turning the follow-up burden into a cost center for itself or the wider healthcare system. | Medium | SR001, SR002, SR006, SR010 |
| CV001 | The best-supported valuation reading is a reported figure near $7 billion rather than a company-confirmed mark. | High | SV004, SV005, SV006, SV007 |
| CV002 | Using the GetLatka revenue estimate, that reported valuation implies a very high revenue multiple for a company still in clinic-build mode. | High | SV010, SV002, SV009 |
| CV003 | The jump from the Series B to the Series C looks like a major step-up in investor conviction and narrative confidence. | Medium | SV010, SV002 |
| CV004 | The upside case depends on U.S. clinic replication, repeat annual usage, and a durable premium consumer brand. | Medium | SV006, SV011, SV008 |
| CV005 | A reasonable downside band based on public data is well below the headline mark if repeat behavior or expansion underperform. | Medium | SV008, SV009 |
| CV006 | The mark is imprecise because the company has not published audited revenue, margin, or cash-balance data. | Medium | SV003, SV007, SV010 |
| CV007 | Compared with MRI-based preventive peers, Neko appears more polished on experience but less proven on scale economics. | Medium | SV011, SV007, SV003 |
| CV008 | The most defensible stance is that the valuation is expensive but still investable if the U.S. rollout proves repeatable. | Medium | SV006, SV009, SV008 |
| CV009 | The public source set does not support treating the $7 billion figure as a precise mark, only as a reported range. | High | SV007, SV002, SV003 |
| CV010 | The company’s brand, waitlist, and growth help explain the premium, but they do not by themselves justify it. | Medium | SV007, SV011, SV009 |
| CV011 | The estimated 2025 revenue is small relative to the valuation, so the market is clearly pricing future scale. | Medium | SV003, SV006, SV007 |
| CV012 | The valuation thesis remains tied to expansion and repeat behavior rather than already-proven earnings power. | Medium | SV004, SV006, SV007 |
| ID | Publisher | Title | Quote |
|---|---|---|---|
| SO001 | TechCrunch | Daniel Ek's Neko Health raises $65M for preventative healthcare ... | Neko Health has raised €60M in its first external round of funding. |
| SO002 | TechCrunch | What Funding Has Neko Health Raised? Full Round History & Key ... | Neko’s promised U.S. expansion arrives on September 24, when the health-scanning startup opens its first American office. |
| SO003 | ToFlow | Neko Health raises $700m Series C ahead of US launch | Neko Health has successfully raised funds through 3 rounds, with the latest being a Series C led by Lightspeed Venture Partners. |
| SO004 | Angel Investors Network | Neko Health $700M Series C at ~$7B Valuation | The $700 million figure is company-confirmed. The ~$7 billion valuation is not. |
| SO005 | Tech Funding News | Daniel Ek's body-scanning startup Neko Health opens first ... | Neko Health raised $700m Series C ahead of US launch. |
| SO006 | ValueAddVC | Neko Health | A Completely New Healthcare Experience | A $700 million check from Lightspeed and O.G. Venture Partners is real capital, but the ~$7 billion number attached to it is a media estimate. |
| SO007 | Tracxn | Mark Zuckerberg backs Daniel Ek's health tech startup in ... | Neko Health is a series C company based in Stockholm (Sweden), founded in 2018 by Daniel Ek and Hjalmar Nilsonne. |
| SO008 | Clay | Neko Health Valuation, Funding & Investors | Neko Health has successfully raised funding over three rounds, with the latest being a $700 million Series C. |
| SM001 | Fierce Healthcare | Neko Health - Jobs | At £299 ... a single scan isn't cheap |
| SM002 | TechFundingNews | Neko Health – What People Are Missing | the company, co-founded by Spotify chief executive Daniel Ek |
| SM003 | Healthy Debate | Neko Health Jobs & Careers | Health eCareers | The primary critique of Neko is that increased screening increases healthcare costs |
| SM004 | Scaling Care | Daniel Ek's body-scanning startup Neko Health opens first ... | The mass of cost and harm sits below the surface in the follow-up cascade |
| SM005 | Newmarket Pitch | Neko Health | A Completely New Healthcare Experience | A 30,000-scan site could produce almost £9 million a year |
| SM006 | TechCrunch | Mark Zuckerberg backs Daniel Ek's health tech startup in ... | more than 25,000 New Yorkers have joined a waitlist |
| SM007 | eMarketer | How Much Did Neko Health Raise? Funding & Key Investors | Ezra and Prenuvo ... options ranging from $1,000 to upward of $2,700 |
| SM008 | Tracxn | Full body medical scanning startup Neko Health nabs $260 ... | Neko Health has 138 active competitors |
| SP001 | TechFundingNews | Neko Health eyes US launch after $700M raise - MedTech World | Prenuvo, which offers whole-body MRI scans, has raised $192 million |
| SP002 | Multiples VC | Clinical Practice Lead @ Neko Health | Atomico Job Board | Neko Health valuation has grown 3.9x from $1.8B to $7B |
| SP003 | GetLatka | Daniel Ek's body-scanning startup Neko Health opens first ... | Neko Health generated an estimated $21.9M in annual revenue in 2025 |
| SP004 | eMarketer | Neko Health | A Completely New Healthcare Experience | options ranging from $1,000 to upward of $2,700 |
| SP005 | Tracxn | Mark Zuckerberg backs Daniel Ek's health tech startup in ... | Neko Health has 138 active competitors |
| SP006 | Value Add VC | How Much Did Neko Health Raise? Funding & Key Investors | A ~$7B valuation implies a huge multiple on a company with a handful of clinics and no disclosed revenue |
| SP007 | Fierce Healthcare | Full body medical scanning startup Neko Health nabs $260 ... | At £299 ... a single scan isn't cheap |
| SP008 | TechCrunch | Full body medical scanning startup Neko Health nabs $260 ... | more than 25,000 New Yorkers have joined a waitlist |
| SP009 | HealthTech Alpha | Neko Health eyes US launch after $700M raise - MedTech World | Neko Health | Partnerships |
| SI001 | fiercehealthcare.com | Neko Health scores $700M backed by tech investors, celebrities | Neko Health scores $700M backed by tech investors, celebrities |
| SI002 | valueaddvc.com | $700M at $7B — Neko Health Body-Scan Startup | $700M at $7B — Neko Health Body-Scan Startup |
| SI003 | hitconsultant.net | Neko Health Secures $700M to Fund U.S. Preventive ... | Neko Health Secures $700M to Fund U.S. Preventive ... |
| SI004 | techcrunch.com | Daniel Ek's body-scanning startup Neko Health opens first ... | Daniel Ek's body-scanning startup Neko Health opens first ... |
| SI005 | Fierce Healthcare | Neko Health scores $700M backed by tech investors, celebrities | At £299 ... a single scan isn't cheap |
| SI006 | techfundingnews.com | Mark Zuckerberg backs Daniel Ek's health tech startup in ... | Mark Zuckerberg backs Daniel Ek's health tech startup in ... |
| SI007 | startupmafia.eu | Stockholm-based Neko Health raises €612.7M Series C to ... | Stockholm-based Neko Health raises €612.7M Series C to ... |
| SI008 | nekohealth.com | Neko Health raises $260m Series B led by Lightspeed | Neko Health raises $260m Series B led by Lightspeed |
| SI009 | Neko Health | Neko Health | A Completely New Healthcare Experience | The Neko Health Scan checks your heart, skin, blood, and metabolic health in one hour. |
| SI010 | valueaddvc.com | $700M at $7B — Neko Health Body-Scan Startup | $700M at $7B — Neko Health Body-Scan Startup |
| SI011 | Multiples | Neko Health Secures $700M to Fund U.S. Preventive ... | Neko Health Secures $700M to Fund U.S. Preventive ... |
| SI012 | techcrunch.com | Daniel Ek's body-scanning startup Neko Health opens first ... | Daniel Ek's body-scanning startup Neko Health opens first ... |
| SE001 | PHILIPPS & BYRNE | Neko: Health, Licence & Alternatives (2026) - IdeaProof | Neko has developed a new medical scanning technology concept to make it possible to do broad and non-invasive health data collection. |
| SE002 | Built In | Backend Engineer, Health Data Platform at Neko Health | Apply now! | Neko Health is looking for a Workday Integration Specialist to own the design, build, and maintenance of integrations between Workday and our wider systems landscape. |
| SE003 | Ashby | Jack Edney - Neko Health - LinkedIn | Neko Health is looking for a Workday Integration Specialist to own the design, build, and maintenance of integrations between Workday and our wider systems landscape. |
| SE004 | Simplify | Daniel Ek's body-scanning startup Neko Health opens first ... | Neko Health is an actively verified employer hiring talent across technology, engineering, and operations. |
| SE005 | StudySmarter | Neko Health | A Completely New Healthcare Experience | A healthcare technology company in Greater London seeks a Backend Engineer to build and develop a secure health data platform. |
| SE006 | StudySmarter | Mark Zuckerberg backs Daniel Ek's health tech startup in ... | The role is part of cross-functional teams and offers an opportunity to impact preventive healthcare significantly. |
| SE007 | Joinrise | How Much Did Neko Health Raise? Funding & Key Investors | Neko Health is a healthcare technology company focused on preventive healthcare and early detection. |
| SE008 | Workly | Full body medical scanning startup Neko Health nabs $260 ... | Design and maintain Workday integrations to enhance data flow and system capabilities. |
| SE010 | Neko Health | Neko Health raises €60m Series A led by Lakestar | Neko Health closes a €60m Series A led by Lakestar, its first outside funding, to expand preventive healthcare across Europe after a ... |
| SE011 | Neko Health | Neko Health raises $700m Series C ahead of US launch | Neko Health raises $700m Series C ahead of US launch. With its first US clinics opening in New York and other cities this year, Neko will ... |
| SU001 | TechCrunch | Neko Health – Case Study | Philipps & Byrne | Neko’s promised U.S. expansion arrives on September 24, when the health-scanning startup opens its first American office. |
| SU002 | MedTech World | The Case for Neko Health - Scaling Care by Simon Krivda | Neko Health has developed the Neko Health Scan, a 60-minute, non-invasive and radiation-free assessment that combines proprietary sensors with blood analysis. |
| SU003 | Renascence | Neko Health - Partnerships, Customers, Strategics | Preventive health is, at its heart, a customer-experience design challenge. |
| SU004 | New Market Pitch | Neko Health - Atomico | Neko Health can become a major global preventive-health company, but it cannot scale like Spotify under its current one-hour, clinic-based delivery model. |
| SU005 | Scaling Care | Daniel Ek's body-scanning startup Neko Health opens first ... | The scan is the smallest line item. The mass of cost and harm sits below the surface in the follow-up cascade. |
| SU006 | PHILIPPS & BYRNE | Neko Health | A Completely New Healthcare Experience | Neko has developed a new medical scanning technology concept to make it possible to do broad and non-invasive health data collection. |
| SU007 | HealthTech Alpha | Mark Zuckerberg backs Daniel Ek's health tech startup in ... | Neko Health is a Swedish health-tech company co-founded in 2018 by Hjalmar Nilsonne and Daniel Ek. |
| SU008 | Clay | Neko Health $700M Round: Preventive Health as CX Design | Neko Health has successfully raised funding over three rounds, with the latest being a $700 million Series C. |
| SU009 | Trustpilot | Neko Health – Case Study | Philipps & Byrne | Customer reviews provide a public sentiment signal. |
| SU013 | EquityZen | Neko Health - Partnerships, Customers, Strategics | Neko Health company profile and market signal. |
| SR001 | Built In | Workday Integration Specialist - Neko Health | Neko Health is looking for a Workday Integration Specialist to own the design, build, and maintenance of integrations between Workday and our ... |
| SR002 | Simplify | Jobs and Employment at Neko Health | What sets Neko Health apart is its explicit focus on data privacy and control, aligning with EU data protection rules, alongside a straightforward subscription ... |
| SR005 | TechCrunch | Daniel Ek's body-scanning startup Neko Health opens first ... | Neko Health's promised U.S. expansion arrives on September 24, when the health-scanning startup opens its first American office. |
| SR006 | Neko Health | Neko Health | A Completely New Healthcare Experience | The Neko Health Scan checks your heart, skin, blood, and metabolic health in one hour, with results explained by a clinician. |
| SR007 | Tech Funding News | Mark Zuckerberg backs Daniel Ek's health tech startup in ... | Spotify founder Daniel Ek's Neko Health raises a massive $700M Series C, backed by Mark Zuckerberg, to bring its £299 body-scan clinics to ... |
| SR008 | Neko Health | Neko Health raises $700m Series C ahead of US launch | Neko Health raises $700m Series C ahead of US launch. With its first US clinics opening in New York and other cities this year, Neko will ... |
| SR009 | Wall Street Journal | Neko Health, a Body-Scan Startup, Raises $700 Million in ... | Body-scanning technology startup Neko Health raised $700 million in a Series C funding round. The company plans to use the funding to launch its ... |
| SR010 | The New York Times | Tech Investors and Longevity Influencers Back Neko Health's Mega ... | Its aim is to promote disease prevention and boost longevity rates. A Neko Health scan in Britain is priced at 299 pounds ($400), which the ... |
| SR012 | Healthy Debate | Neko Health – What People Are Missing | Neko's method is non-invasive, low-cost, and takes only 15 minutes. This makes it possible to create a new behaviour: an annual Neko health ... |
| SV001 | Trustpilot | Neko Health Reviews - Trustpilot | Do you agree with Neko Health's 4-star rating? Check out what 402 people have written so far, and share your own experience. |
| SV002 | EquityZen | Invest In Neko Health Stock | Buy Pre-IPO Shares - EquityZen | Neko Health is a health-tech company focused on creating a healthcare system that emphasizes preventive measures and early detection of health issues. |
| SV003 | VentureBurn | Daniel Ek's Neko Health Raises $700 Million for US Launch | The $700M funding round led by Lightspeed Venture Partners propels Neko Health to a valuation of nearly $7 billion. This represents a massive ... |
| SV004 | Neko Health | Neko Health raises €60m Series A led by Lakestar | Neko Health closes a €60m Series A led by Lakestar, its first outside funding, to expand preventive healthcare across Europe after a ... |
| SV005 | Neko Health | Neko Health raises $260m Series B led by Lightspeed | Neko Health closes a $260m Series B led by Lightspeed to expand preventive healthcare across Europe and the US, after 10000 scans and a ... |
| SV006 | Neko Health | Neko Health raises $700m Series C ahead of US launch | Neko Health raises $700m Series C ahead of US launch. With its first US clinics opening in New York and other cities this year, Neko will ... |
| SV007 | Wall Street Journal | Neko Health, a Body-Scan Startup, Raises $700 Million in ... | Body-scanning technology startup Neko Health raised $700 million in a Series C funding round. The company plans to use the funding to launch its ... |
| SV008 | ValueAddVC | $700M at $7B — Neko Health Body-Scan Startup | A $700 million check from Lightspeed and O.G. Venture Partners is real capital, but the ~$7 billion number attached to it is a media estimate. |
| SV009 | eMarketer | Full body medical scanning startup Neko Health nabs $260 ... | Neko Health secures $260M in Series B funding: The medical scanning startup is now valued at $1.8 billion, which feels overblown when you ... |
| SV010 | GetLatka | Neko Health Revenue, Valuation & Funding (2025) | Neko Health reached a $1.8B valuation in 2025, set during its Series B round. Neko Health has raised $325M in total funding across 2 rounds, ... |
| SV011 | TechCrunch | Daniel Ek's body-scanning startup Neko Health opens first ... | Neko Health's promised U.S. expansion arrives on September 24, when the health-scanning startup opens its first American office. |